244 related articles for article (PubMed ID: 31167168)
1. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.
Coopmans EC; van Meyel SWF; Pieterman KJ; van Ipenburg JA; Hofland LJ; Donga E; Daly AF; Beckers A; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2019 Aug; 181(2):K21-K27. PubMed ID: 31167168
[TBL] [Abstract][Full Text] [Related]
2. Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors.
Raverot G; Vasiljevic A; Jouanneau E; Lasolle H
Eur J Endocrinol; 2019 Aug; 181(2):C1-C3. PubMed ID: 31167164
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide: A potential therapeutic alternative for resistant prolactinoma.
Lasolle H; Vasiljevic A; Borson-Chazot F; Raverot G
Ann Endocrinol (Paris); 2019 Apr; 80(2):84-88. PubMed ID: 30318256
[TBL] [Abstract][Full Text] [Related]
4. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
5. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
6. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
8. Refractory lactotroph adenomas.
Urwyler SA; Karavitaki N
Pituitary; 2023 Jun; 26(3):273-277. PubMed ID: 36928728
[TBL] [Abstract][Full Text] [Related]
9. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
Shimon I
Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
[TBL] [Abstract][Full Text] [Related]
10. Medical approach to pituitary tumors.
Neggers SJ; van der Lely AJ
Handb Clin Neurol; 2014; 124():303-16. PubMed ID: 25248595
[TBL] [Abstract][Full Text] [Related]
11. Prolactinomas in males: any differences?
Duskin-Bitan H; Shimon I
Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
13. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
[TBL] [Abstract][Full Text] [Related]
16. Management of Dopamine Agonist-Resistant Prolactinoma.
Maiter D
Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
18. A case of a prolactinoma resistant to dopamine agonists.
Vourliotaki I; Bonapart IE; Stamataki C; Tsapakis EM; Saridaki C
Hormones (Athens); 2005; 4(3):165-70. PubMed ID: 16613827
[TBL] [Abstract][Full Text] [Related]
19. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.
Meyer P; Bohnen NI; Barkan AL; Shapiro B
Nuklearmedizin; 1999; 38(2):66-7. PubMed ID: 10100234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
